Next Article in Journal
Sequential Multiple Imputation for Real-World Health-Related Quality of Life Missing Data after Bariatric Surgery
Previous Article in Journal
Does Oral Health-Related Quality of Life Differ by Income Group? Findings from a Nationally Representative Survey
Previous Article in Special Issue
Posterior Tibial Nerve Stimulation in Children with Lower Urinary Tract Dysfunction: A Mixed-Methods Analysis of Experiences, Quality of Life and Treatment Effect
 
 
Systematic Review
Peer-Review Record

Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review

Int. J. Environ. Res. Public Health 2022, 19(17), 10825; https://doi.org/10.3390/ijerph191710825
by John W. Yuen 1,*, Ricky W. Wu 2, Shirley S. Ching 1 and Chi-Fai Ng 3
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3:
Int. J. Environ. Res. Public Health 2022, 19(17), 10825; https://doi.org/10.3390/ijerph191710825
Submission received: 17 July 2022 / Revised: 25 August 2022 / Accepted: 26 August 2022 / Published: 30 August 2022
(This article belongs to the Special Issue Quality of Life and Outcomes of Patients with Urological Diseases)

Round 1

Reviewer 1 Report

This article proposes an unrevealed issue of the impact of intravesical modalities on patients’ quality of life. These intravesical modalities are indeed more effective for NMIBC than systemic chemotherapy, whereas the recent evidence of the QoL of patients after receiving intravesical modalities remains inconsistent. Authors exhaustively collated the current QoL-related evidence and pointed out this problematic issue of the field that may be attractive for the readership.

 

1. Some issues should be further described or clarified.

For the broader readership, authors could add the advantage of intravesical therapies, the characteristic of bladder urothelium that facilitates the practice of intravesical therapies, and the applications of intravesical drug delivery to bladder disorders other than bladder cancer.

Authors could add the utilisation rates of intravesical modalities in NMIBC.

 

2. Some problems should be amended, which are as follows:

Consort 2010 checklist should be “CONSORT” 2010 checklist.

Strobe statement checklist should be “STROBE” statement checklist.

In line 25, “lacking for” is wrong grammar.

In line 28, “uncover” may not be the optimal description. Perhaps “clarify”.

In line 29, “demands for” is wrong, just “demands”.

In line 54, lacking data “of”.

Line 60. “while they were improved…” should be “,these symptoms were improve…”

Line 67. “new modalities emerged to demonstrate at least comparable if not better prophylactic effectiveness but less toxicities” is confused. Please check the grammar.

In lines 92-94. Is “therap” a typo?

In line 144. Is {Williams-Cox, 2004} the reference?

In line 395. and 10 studies “focusing” on chemotherapy

Author Response

As attached. 

Author Response File: Author Response.docx

Reviewer 2 Report

This is a well written manuscript about QoL in patients with bladder cancer.

I have no major comment. I would suggest to the authors to include in the discussion a comment also about follow-up and diagnosis in these patients, that could seriously affect the QoL. The importance of new technologies, could be an important aspect, as for example MRI (please see the manuscript by Delli Pizzi et al. 10.1007/s00330-020-07473-6). Authors should consider to discuss the beneficial effect of these technologies.

Author Response

As attached.

Author Response File: Author Response.docx

Reviewer 3 Report

Please see the attachment

Comments for author File: Comments.pdf

Author Response

As attached.

Author Response File: Author Response.docx

Back to TopTop